Want to see WVE full AI Analyst Report?
WVE Stock Chart & Stats
$5.25
$0.12(2.07%)
At close: 4:00 PM EDT
$5.25
$0.12(2.07%)
Day’s Range― - ―
52-Week Range$4.65 - $21.73
Previous CloseN/A
Volume649.21K
Average Volume (3M)3.37M
Market Cap
$957.65M
Enterprise Value$738.28
Total Cash (Recent Filing)$490.60M
Total Debt (Recent Filing)$43.59M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Nov 05, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding197,048,170
10 Day Avg. Volume3,581,413
30 Day Avg. Volume3,368,701
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.60Price Target Upside235.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.12
Revenue Forecast (FY)$50.34M
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory Pipeline MomentumProgress across multiple clinical programs reduces reliance on a single asset and creates several potential routes to future product revenue. Phase IIa execution for WVE-007 and FDA engagement for WVE-006 also provide durable development and regulatory catalysts beyond one reporting period.
Substantial Cash RunwayA cash position supporting operations into Q3 2028 gives Wave time to advance clinical programs without immediate dependence on capital markets. This financial visibility can support disciplined development, preserve strategic flexibility, and allow value-creating milestones to mature.
Differentiated RNA Platform And Broad OpportunitiesA proprietary chemistry and modality platform can support repeatable development across several serious diseases rather than limiting the company to one therapeutic candidate. Its obesity, AATD, and liver-disease programs provide multiple opportunities to demonstrate durable platform value.
Bears Say
Persistent Losses And Cash BurnLarge operating losses and substantial cash outflows show that Wave has not yet achieved commercial operating leverage. Continued investment in development may require future financing or partnership receipts, potentially limiting capital allocation flexibility if commercialization remains distant.
Sharp Decline In Collaboration RevenueThe steep collaboration-revenue decline highlights the variability of Wave’s current revenue base and its dependence on partner-related receipts before product commercialization. Lower recurring or predictable revenue can make funding plans more sensitive to milestone timing and development outcomes.
Clinical And Regulatory Execution UncertaintyWave’s value creation depends on successful trials, defined regulatory requirements, and timely partnering decisions, none of which are assured by current progress. Delays, additional evidence requirements, or changes to the DMD strategy could extend the path to approvals and commercial revenue.
Wave Life Sciences News
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $4.64 and its highest was $21.73 in the past 12 months.
What is Wave Life Sciences’s market cap?
Wave Life Sciences’s market cap is $957.65M.
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Jul 30, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.04.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -0.32.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 197,048,170 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -0.861%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Currently, no hedge funds are holding shares in WVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.60 (235.24% Upside)
$17.60 (235.24% Upside)
Blogger Sentiment
Neutral
WVE Sentiment 50%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 672.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
121.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
WVE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical momentum across the lead programs (WVE-007, WVE-006, WVE-008) with compelling early human and preclinical data, regulatory engagement (FDA meeting for 006), and a solid cash balance supporting operations into Q3 2028. Offsetting these positives are a pronounced YoY revenue decline (-73.6%), rising R&D and G&A spend driving a larger net loss (+37.4% YoY), dependency on future milestone payments not included in runway calculations, and timing/regulatory uncertainties (including partnership-driven strategy for DMD). On balance, the clinical and platform progress and runway position are dominant positives despite near-term financial headwinds and program/timing uncertainties.View all WVE earnings summariesWVE Stock 12 Month Forecast
Average Price Target
$17.60
▲(235.24% Upside)
Technical Analysis
Precigen
―
Stoke Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Rapport Therapeutics, Inc.
―
Ownership Overview
28.49% Insiders
14.24% Mutual Funds
0.22% Other Institutional Investors
48.29% Public Companies and Individual Investors